Contineum Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
CTNM$10.56+2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(in thousands, except share data)
| Convertible Preferred Stock · Class A and Class BCommon Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveIncome · AccumulatedDeficit · TotalStockholders’Equity (Deficit) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount | ||||||||||||||||
| Balance at December 31, 2023 | 15,906,236 | $192,620 | 2,349,554 | $2 | $7,098 | $108 | $(75,144) | $(67,936) | ||||||||
| Issuance of common stock in connection with initial public offering, net of issuance costs of $10,912 | — | — | 7,423,682 | 7 | 107,860 | — | — | 107,867 | ||||||||
| Conversion of convertible preferred stock to common stock upon initial public offering | (15,906,236) | (192,620) | 15,906,236 | 17 | 192,603 | — | — | 192,620 | ||||||||
| Reclassification of warrant from liability to equity | — | — | — | — | 216 | — | — | 216 | ||||||||
| Shares purchased through employee stock purchase plan | — | — | 17,996 | — | 385 | — | — | 385 | ||||||||
| Exercise of stock options | — | — | 157,081 | — | 405 | — | — | 405 | ||||||||
| Stock-based compensation | — | — | — | — | 6,804 | 6,804 | ||||||||||
| Net loss | — | — | — | — | — | — | (42,258) | (42,258) | ||||||||
| Unrealized loss on marketable securities | — | — | — | — | — | (37) | — | (37) | ||||||||
| Balance at December 31, 2024 | — | $— | 25,854,549 | $26 | $315,371 | $71 | $(117,402) | $198,066 | ||||||||
| Issuance of common stock in follow-on public offering, net of issuance costs of $6,219 | — | — | 8,097,570 | 8 | 92,968 | — | — | 92,976 | ||||||||
| Issuance of common stock in at-the-market offering, net of issuance costs | — | — | 3,241,110 | 3 | 19,009 | — | — | 19,012 | ||||||||
| Exercise of stock options | — | — | 42,653 | — | 219 | — | — | 219 | ||||||||
| Shares purchased through employee stock purchase plan | — | — | 84,243 | — | 467 | — | — | 467 | ||||||||
| Stock-based compensation | — | — | — | — | 10,038 | — | — | 10,038 | ||||||||
| Net loss | — | — | — | — | (59,978) | (59,978) | ||||||||||
| Unrealized gain on marketable securities | — | — | — | — | — | 189 | — | 189 | ||||||||
| Balance at December 31, 2025 | — | $— | 37,320,125 | $37 | $438,072 | $260 | $(177,380) | $260,989 | ||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.